These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 19095950)
41. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226 [TBL] [Abstract][Full Text] [Related]
42. Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling. Tian J; Yuan L Biomed Pharmacother; 2018 Oct; 106():109-116. PubMed ID: 29957460 [TBL] [Abstract][Full Text] [Related]
43. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Marchal S; Galenne T; Juin P; Becuwe P; Merlin JL Cancer Gene Ther; 2009 Jun; 16(6):498-507. PubMed ID: 19165235 [TBL] [Abstract][Full Text] [Related]
45. MAGI3 Suppresses Glioma Cell Proliferation via Upregulation of PTEN Expression. Ma Q; Zhang Y; Meng R; Xie KM; Xiong Y; Lin S; He ZL; Tao T; Yang Y; Zhao JZ; He JQ Biomed Environ Sci; 2015 Jul; 28(7):502-9. PubMed ID: 26248734 [TBL] [Abstract][Full Text] [Related]
46. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140 [TBL] [Abstract][Full Text] [Related]
47. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. Nowak DG; Katsenelson KC; Watrud KE; Chen M; Mathew G; D'Andrea VD; Lee MF; Swamynathan MM; Casanova-Salas I; Jibilian MC; Buckholtz CL; Ambrico AJ; Pan CH; Wilkinson JE; Newton AC; Trotman LC J Cell Biol; 2019 Jun; 218(6):1943-1957. PubMed ID: 31092557 [TBL] [Abstract][Full Text] [Related]
48. Reciprocal negative feedback regulation of ATF6α and PTEN promotes prostate cancer progression. Feng T; Zhao R; Zhang H; Sun F; Hu J; Wang M; Qi M; Liu L; Gao L; Xiao Y; Zhen J; Chen W; Wang L; Han B Cell Mol Life Sci; 2023 Sep; 80(10):292. PubMed ID: 37715829 [TBL] [Abstract][Full Text] [Related]
49. PTEN, more than the AKT pathway. Blanco-Aparicio C; Renner O; Leal JF; Carnero A Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655 [TBL] [Abstract][Full Text] [Related]
50. Sprouty genes function in suppression of prostate tumorigenesis. Schutzman JL; Martin GR Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20023-8. PubMed ID: 23150596 [TBL] [Abstract][Full Text] [Related]
51. SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma. Yu C; Zhang B; Li YL; Yu XR Biomed Pharmacother; 2018 Sep; 105():10-17. PubMed ID: 29807230 [TBL] [Abstract][Full Text] [Related]
52. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Kim JH; Kang TH; Noh KH; Kim SH; Lee YH; Kim KW; Bae HC; Ahn YH; Choi EY; Kim JS; Lee KM; Kim TW Immunol Lett; 2010 Nov; 134(1):47-54. PubMed ID: 20727912 [TBL] [Abstract][Full Text] [Related]
53. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer. Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574 [TBL] [Abstract][Full Text] [Related]
54. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Kim TH; Yoo JY; Kim HI; Gilbert J; Ku BJ; Li J; Mills GB; Broaddus RR; Lydon JP; Lim JM; Yoon HG; Jeong JW Cancer Res; 2014 Dec; 74(24):7371-82. PubMed ID: 25377472 [TBL] [Abstract][Full Text] [Related]
55. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391 [TBL] [Abstract][Full Text] [Related]
56. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373 [TBL] [Abstract][Full Text] [Related]
57. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC. Lee JS; Lero MW; Mercado-Matos J; Zhu S; Jo M; Tocheny CE; Morgan JS; Shaw LM Cell Rep; 2022 Dec; 41(10):111759. PubMed ID: 36476848 [TBL] [Abstract][Full Text] [Related]
58. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033 [TBL] [Abstract][Full Text] [Related]
59. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion. Joshi A; Miller C; Baker SJ; Ellenson LH Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082 [TBL] [Abstract][Full Text] [Related]
60. DGCR8 is essential for tumor progression following PTEN loss in the prostate. Belair CD; Paikari A; Moltzahn F; Shenoy A; Yau C; Dall'Era M; Simko J; Benz C; Blelloch R EMBO Rep; 2015 Sep; 16(9):1219-32. PubMed ID: 26206718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]